Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
BI BIIB BIOGEN INC. FY ended Feb 04, 2026 | $218.50 | $32.26B | $29.36B | $9.89B | $2.60B | $1.29B | 24.86x | 3.26x | 10.24x |
LL LLY ELI LILLY & Co FY ended Feb 09, 2026 | $1,174.61 | $1.11T | $1.16T | $65.18B | $28.02B | $20.64B | 51.18x | 16.96x | 40.66x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 23.71x | 4/4 | -$9.05B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 6.60x | 4/4 | $272.11M | $4.33 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 6.55x | 4/4 | -$2.62B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
BI BIIB BIOGEN INC. FY ended Feb 04, 2026 | $218.50 | $32.26B | $29.36B | $9.89B | $2.60B | $1.29B | 24.86x | 3.26x | 10.24x |
LL LLY ELI LILLY & Co FY ended Feb 09, 2026 | $1,174.61 | $1.11T | $1.16T | $65.18B | $28.02B | $20.64B | 51.18x | 16.96x | 40.66x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 23.71x | 4/4 | -$9.05B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 6.60x | 4/4 | $272.11M | $4.33 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 6.55x | 4/4 | -$2.62B | — | Target fundamentals do not produce a usable positive equity value. |
